NCT06279234View on ClinicalTrials.gov

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

April 11, 2025

Study Completion Date

April 11, 2025

Conditions
Type 2 Diabetes Mellitus (T2DM)Obesity
Interventions
DRUG

Placebo

Oral tablet

DRUG

Rosuvastatin

Oral tablet

DRUG

Midazolam

Oral suspension

DRUG

Omeprazole

Oral tablet

DRUG

PF-06954522

Oral tablet

Trial Locations (2)

33143

Qps-Mra, Llc, South Miami

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06279234 - A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter